Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, dose escalation, Phase 1 study of oral LGH447 in Japanese
patients with relapsed and/or refractory multiple myeloma for which no standard effective
treatment options exist.
The study consists of a dose escalation part to estimate the maximum tolerated dose and/or
the recommended dose for expansion and a dose expansion part to further assess safety and
preliminary anti-cancer activity of LGH447 at the maximum tolerated dose and/or the
recommended dose for expansion.